Clinical trial
A Randomized, Double-blind, Placebo Controlled Study Assessing the Efficacy and Safety of Vilazodone 40 mg qd and Evaluating Genetic Biomarkers Associated With Treatment Response in Patients With Major Depressive Disorder (MDD)
NCT00683592 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo Controlled Study Assessing the Efficacy and Safety of Vilazodone 40 mg qd and Evaluating Genetic Biomarkers Associated With Treatment Response in Patients With Major Depressive Disorder (MDD)
- Lead sponsor
- Forest Laboratories
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 31, 2008
- Completion date
- March 31, 2009
- Enrollment
- 481 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.